A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO

CompletedOBSERVATIONAL

Enrollment

1,350

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions

Neovascular Age-related Macular DegenerationRetinal Vein Occlusion

Interventions

DRUG

anti-VEGF treatment

Follow clinical practice/administration

Trial Locations (1)

Bayer, Mississauga